1
|
|
2
|
|
3
|
Abstract
Thrombotic microangiopathy can manifest in a diverse range of diseases and is characterized by thrombocytopenia, microangiopathic hemolytic anemia, and organ injury, including AKI. It can be associated with significant morbidity and mortality, but a systematic approach to investigation and prompt initiation of supportive management and, in some cases, effective specific treatment can result in good outcomes. This review considers the classification, pathology, epidemiology, characteristics, and pathogenesis of the thrombotic microangiopathies, and outlines a pragmatic approach to diagnosis and management.
Collapse
Affiliation(s)
- Vicky Brocklebank
- National Renal Complement Therapeutics Centre, Newcastle upon Tyne, Hospitals National Health Service Foundation Trust, Newcastle upon Tyne, UK
- Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK; and
| | - Katrina M. Wood
- Department of Cellular Pathology, Newcastle upon Tyne Hospitals National Health Service Foundation Trust, Newcastle upon Tyne, UK
| | - David Kavanagh
- National Renal Complement Therapeutics Centre, Newcastle upon Tyne, Hospitals National Health Service Foundation Trust, Newcastle upon Tyne, UK
- Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK; and
| |
Collapse
|
4
|
|
5
|
Affiliation(s)
- G Tchernia
- Laboratoire d'Hématologie, Hôpital de Bicêtre, Kremlin-Bicêtre, France
| |
Collapse
|
6
|
Affiliation(s)
- C Williams
- Mount Sinai Medical Center, New York, N.Y
| | | | | |
Collapse
|
7
|
Affiliation(s)
- C Mueller-Eckhardt
- Institute of Clinical Immunology and Transfusion Medicine, Justus Liebig University, Giessen, FRG
| |
Collapse
|
8
|
Kiprov DD, Kwiatkowska BJ, Miller RG. Therapeutic apheresis in human immunodeficiency virus-related syndromes. Curr Stud Hematol Blood Transfus 2015:184-97. [PMID: 2148717 DOI: 10.1159/000418559] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- D D Kiprov
- Department of Medicine, Children's Hospital of San Francisco, Calif
| | | | | |
Collapse
|
9
|
Woźniak K, Urbanowska E, Snarski E. [Plasmapheresis in haematology]. Wiad Lek 2015; 68:173-178. [PMID: 26181153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Plasmapheresis also known as a therapeutic plasma exchange (TPE) is a procedure of plasma removal with it's ineligible plasma's component. Usually it is a supportive measure used simultaneously with the treatment, but in a few diseases, e.g. in trombotictrombocytopenic purpura (TTP), it is a first-choice treatment. During the plasmapheresis plasma is mostly replaced by 20% solution of albumin or combination of 20% solution of albumin and 0.9% solution of NaCl, however in some diseases fresh frozen plasma (FFP) is used. Plasmaphereses have found a wide application in different branches of medicine: hematology, neurology, nephrology, reumatology. Plasmapheresis is an invasive procedure, but when performed by qualified staff it is rather safe and serious complications are very rare.The most common complications of plasmapheresis are mild, usually caused by electrolyte disturbances (hypokalemia, hypokalcemia) or anticoagulation. More serious complication can be associated with FFP transfusion, extracorporeal circulation or presence of intravenous catheter. The latter one is usually necessary to perform the plasmapheresis. In haematology the most common indication for plasmapheresis is the supportive treatment of multiple myeloma. The procedure is performed in patients with high protein levels endangered with hyperviscosity syndrome. Less frequent indications to plasmapheresis in haematology are: Waldenström's macroblobulynaemia, idiopathic thrombocytopenic purpura (ITP), pure red cell aplasia (PRCA), polyneuropaties connected with haematological disorders. Supportive treatment of haemofagocytic syndrome (HLH--hemophagocytic lymphohistiocytosis) is one of the new indications. Plasmaphereses are used in treatment of about 150 different diseases and more and more new needs for this method are identified.
Collapse
|
10
|
Sun SJ, Huang SL. [Clinical experience of Dr. Huang Shi-lin in diagnosing and treating immune thrombocytopenia]. Zhongguo Zhong Xi Yi Jie He Za Zhi 2014; 34:619-621. [PMID: 24941856] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
|
11
|
Hoque MM, Rahman M, Rahman SM, Habibullah MM, Faruki MA, Rahman KH, Mamun AA, Hossain MA. Post-transfusion increment of platelet count in thrombocytopenic patients treated with platelet concentrates. Mymensingh Med J 2013; 22:64-68. [PMID: 23416811] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
The Platelet (PLT) Transfusion Therapy plays an important role in the support of surgical, haematological, oncological and transplant patients. The present study was assigned to find out the post transfusion increment of platelet count among the thrombocytopenic patients in Bangladeshi population. This descriptive study was conducted at the Departments of Haematology and Transfusion Medicine, BSMMU, Dhaka. Total 42 thrmbocytopenic patients were randomly assigned to receive a transfusion when their platelet counts below 10000 per cubic millimeter or with active bleeding. Pre transfusion and post transfusion platelet count were measured in all patients. Out of 42 patients, 26(61.90%) were male and 16(38.10%) were female. Leukemia was the most common cause of thrombocytopenia (47.62%). Most of the patients (71.34%) required transfusion of multiple units of platelet and 12(28.57%) patients required double units. Before transfusion of platelet concentrate <30×10⁸/L, 30-80×10⁸/L and >80×10⁸/L platelet count were found in 30(71.43%), 08(19.05%) and 04(09.52%) patients respectively. After transfusion of platelet concentrate <50×10⁸/L, 50-100×10⁸/L and >100×10⁸/L platelet count were found in 30(71.43%), 08(19.05%) and 04(09.52%) patients respectively. In all patients post transfusion platelet count increases but 2 or multiple units of transfusion were needed.
Collapse
Affiliation(s)
- M M Hoque
- Department of Transfusion Medicine, Dhaka Medical College, Dhaka, Bangladesh. dr_tapan2010@ yahoo.com
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Cataland SR. Recent advances in the management of atypical hemolytic uremic syndrome. Clin Adv Hematol Oncol 2012; 10:537-539. [PMID: 23073053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Affiliation(s)
- Spero R Cataland
- Clinical Internal Medicine, Division of Hematology, Wexner Medical Center, Ohio State University, Columbus, Ohio, USA
| |
Collapse
|
13
|
Khan A, Chaudhry AA, Khan U. Falciparum--the masquerader. J PAK MED ASSOC 2012; 62:62-63. [PMID: 22352106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
The case of a 23-year-old male presenting with a rash on the chest and lower limbs is presented. Work up revealed bicytopenia and plasmodium falciparum on bone marrow biopsy. Treatment with antimalarial drugs resulted in resolution of haematological abnormalities and rash.
Collapse
Affiliation(s)
- Aslam Khan
- Department of Medicine, Combined Military Hospital, Quetta
| | | | | |
Collapse
|
14
|
Chen XY, Li DY, Xu YM. [Chinese medicine treatment of refractory purpura: its advantages and clinical practice]. Zhongguo Zhong Xi Yi Jie He Za Zhi 2011; 31:1033-1035. [PMID: 21910328] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
|
15
|
Cela I, Miller IJ, Katz RS, Rizman A, Shammo JM. Successful treatment of amegakaryocytic thrombocytopenia with eltrombopag in a patient with systemic lupus erythematosus (SLE). Clin Adv Hematol Oncol 2010; 8:806-809. [PMID: 21326158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Affiliation(s)
- Iva Cela
- Division of Hematology, Oncology, and Stem Cell Transplantation, Rush University Medical Center, Chicago, IL 60612, USA,
| | | | | | | | | |
Collapse
|
16
|
|
17
|
Kariuki N. Management of immune thrombocytopaenia in children: a review. East Afr Med J 2009; 86:S84-S88. [PMID: 21591515 DOI: 10.4314/eamj.v86i12.62911] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
OBJECTIVE To provide an overview of the various treatment options available in the rational management of ITP in children. DATA SOURCE Published original research findings and reviews. DATA SELECTION On-line searches for published data on immune thrombocytopaenia, idiopathic thrombocytopaenia, thrombocytopaenic purpura. DATA EXTRACTION Abstracts of selected articles were read and analysed to determine their relevance to this article. DATA SYNTHESIS All relevant articles were read in full and necessary contribution extracted for this review. CONCLUSION Immune thrombocytopaenic purpura is a common disorder affecting children and adults. Ongoing research into the pathogenesis is providing the basis for future treatment options. Greater consensus as to appropriate treatment strategies is needed to improve outcomes.
Collapse
Affiliation(s)
- N Kariuki
- Department of Paediatrics and Child Health, College of Health Sciences, University of Nairobi, P.O. Box 19676-00202, Nairobi, Kenya
| |
Collapse
|
18
|
Nielsen OJ, Friis-Hansen L. [Thrombotic microangiopathies]. Ugeskr Laeger 2009; 171:3614-3620. [PMID: 19954703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
The thrombotic microangiopathic diseases, which include acquired and congenital TTP and HUS, are most frequently acute disease entities. Untreated, these diseases are associated with a lethal course in many cases. Deficiency of the von Willebrand cleaving enzyme, ADAMTS13, is a decisive pathophysiological defect in most cases of thrombotic microangiopathic diseases. Early recognition and a secure distinction from other conditions that resemble TMA diseases is essential in order to institute adequate treatment and to obtain a favourable outcome in terms of both survival and development of serious sequelae.
Collapse
Affiliation(s)
- Ove Juul Nielsen
- Klinisk Biokemisk Afdeling KB3011, Rigshospitalet, DK-2100 København Ø, Denmark
| | | |
Collapse
|
19
|
Branehög I, Olsson KS, Weinfeld A, Domellöf L. Association of hyperthyroidism with idiopathic thrombocytopenic purpura and haemolytic anaemia. Acta Med Scand 2009; 205:125-31. [PMID: 569964 DOI: 10.1111/j.0954-6820.1979.tb06017.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
20
|
Laursen B, Morling N, Rosenkvist J, Sørensen H, Thyme S. Post-transfusion purpura treated with plasma exchange by haemonetics cell separator. A case report. Acta Med Scand 2009; 203:539-43. [PMID: 566507 DOI: 10.1111/j.0954-6820.1978.tb14922.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
A case of post-transfusion purpura in a 61-year-old, multiparous female with a platelet alloantibody (anti-Zwa) in her serum is reported. The patient was successfully treated with plasma exchange by means of a Haemonetics 30 cell separator and corticosteroids. Compared with other therapeutic measures, plasma exchange seems to shorten the duration of thrombocytopenia. Major surgery was possible in our patient within ten days of development of the syndrome.
Collapse
|
21
|
|
22
|
Sweeney JD, Keane FB, Freyne PJ, Temperley IJ, McCann SR. Accessory splenic tissue in a patient with relapsed idiopathic thrombocytopenic purpura. Clin Lab Haematol 2008; 4:309-12. [PMID: 6890886 DOI: 10.1111/j.1365-2257.1982.tb00080.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
23
|
Affiliation(s)
- Richard H Aster
- Department of Medicine, Medical College of Wisconsin, Milwaukee, USA.
| | | |
Collapse
|
24
|
Koçak U, Aral YZ, Kaya Z, Oztürk G, Gürsel T. Evaluation of clinical characteristics, diagnosis and management in childhood immune thrombocytopenic purpura: a single center's experience. Turk J Pediatr 2007; 49:250-255. [PMID: 17990576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
Diagnostic evaluation and management in childhood immune thrombocytopenic purpura (ITP) are controversial. We reviewed the files of 162 children with ITP to evaluate clinical characteristics, response to treatment and outcome. History of antecedent infection, vaccination and serologic evidence for acute viral infection were present in 48%, 5% and 17% of the patients, respectively. At diagnosis, two-thirds of the patients had a platelet count of <10,000/microl but only 10% had major bleedings. Intracranial hemorrhage was seen in two patients (1.2%) with a mortality rate of 0.6%. Sixteen percent developed chronic ITP. The rate of platelet recovery with mega-dose methylprednisolone (30 mg/kg/d for 3 and 20 mg/kg/d for 4 days) was similar to that obtained with intravenous immunoglobulin or oral prednisolone. Four of seven patients with ITP responded to splenectomy. These data show that mode of treatment has no effect on the clinical course and prognosis of childhood ITP.
Collapse
Affiliation(s)
- Ulker Koçak
- Department of Pediatric Hematology, Gazi University Faculty of Medicine, Ankara, Turkey
| | | | | | | | | |
Collapse
|
25
|
Affiliation(s)
- P Lutz
- Unité d'hématologie pédiatrique, hôpital de Hautepierre, 8, avenue Molière, 76400 Strasbourg, France.
| |
Collapse
|
26
|
Abstract
BACKGROUND The 1996 ASH guidelines recommend glucocorticoids and splenectomy as standard treatment of chronic immune thrombocytopenic purpura (ITP). We sought to find out how many German ITP-patients were treated according to these guidelines and whether high-cost treatments were offered to the patients. METHODS We handed out a questionnaire at two self-help group meetings in 2004 and 2005 and to all patients who contacted the ITP self-help group until the end of 2005. RESULTS Eighty-five questionnaires were evaluated. Age (median 34 yr) and gender distribution (38% male, 62% female) were similar to other surveys. Median duration of disease was 5.2 yr. Seventy-five percent had platelets <20,000/microL at the time of diagnosis. Twenty-four percent still had <20,000 platelets/microL at the time of this survey. Forty-two percent had oropharyngeal mucosal bleeds, 28% gastrointestinal or urological bleeds, 11% bleedings in the eye with visual impairment or intracerebral bleeds. 96% had received a trial of glucocorticoid therapy. Seventy-five percent of the patients treated with glucocorticoids perceived this treatment as particularly bothersome. Seventy-five percent of the patients with low platelet count still had their spleen. Complementary and alternative medical treatments had been used by 46% of the patients. Only 33% of the patients had ever heard of rituximab. CONCLUSION Despite literature suggesting that patients wish to be well informed this survey shows that chronic ITP patients know little about their disease and the various treatment modalities. This and the frequent use of complementary and alternative medicines reflects inadequate communication between doctors and ITP patients.
Collapse
Affiliation(s)
- Axel Matzdorff
- Department of Haematology and Oncology, Caritasklinik St Theresia, Saarbruecken, Germany.
| | | |
Collapse
|
27
|
Abstract
Neonatal alloimmune thrombocytopenia (NAIT) occurs when maternal antibodies are directed against antigens on fetal and paternal but not maternal platelets. Most cases of NAIT arise when platelets of the father (and the fetus) express the human platelet antigen (HPA)1a and the mother's platelets expresses HPA-1b. A female patient presented with congenital severe thrombocytopenia and received 4 platelet transfusions, on days 2, 7, 16, and 28. This appeared to be a case of NAIT; however, extensive serologic evaluation by 2 reference laboratories failed to reveal the offending platelet antigen. Consistent with NAIT, the condition resolved by 6 weeks of age. By patient day of life 42, the platelet count had increased without additional need for transfusions, and by 16 weeks, the patient had a completely normal platelet count of 437,000/microL. The patient's platelet count remains normal at a 2-year follow-up. This case is reported as an instructive atypical case of NAIT, in which the relevant platelet antigen could not be identified.
Collapse
Affiliation(s)
- Cindy K Barney
- Neonatal Intensive Care Unit, McKay-Dee Hospital, Intermountain Health Care, 4401 Harrison Boulevard, Ogden, UT 84403, USA.
| | | | | |
Collapse
|
28
|
Abstract
A 35-week pregnant 38-year-old woman presented with isolated thrombocytopenia (platelet count 4 x 10(9)/l). Investigations confirmed immune thrombocytopenic purpura, and she received treatment with prednisolone and intravenous immunoglobulins with no increment in the platelet count. At 37 and 38 weeks of the pregnancy, she received two doses of WinRho (anti-D immunoglobulin) at 50 microg/kg. Five days later, with a platelet count of 46 x 10(9)/l, she had an uncomplicated normal vaginal delivery. WinRho is a useful adjunct to other first-line treatment modalities for immune thrombocytopenia in pregnancy.
Collapse
Affiliation(s)
- K Sieunarine
- Department of Obstetrics and Gynaecology, West Middlesex University Hospital, Middlesex, UK
| | | | | | | |
Collapse
|
29
|
Syed NN, Adil SN, Sajid R, Usman M, Moiz B, Kakepoto GN, Khurshid M. Chronic ITP: analysis of various factors at presentation which predict failure to first line treatment and their response to second line therapy. J PAK MED ASSOC 2007; 57:126-9. [PMID: 17432016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Abstract
OBJECTIVE To observe the significance of various factors in chronic idiopathic thrombocytopenic purpura (ITP) which predict the response of first line (corticosteroids) and second line therapy (splenectomy) and to evaluate their response to second line therapy. METHODS This was a descriptive, prospective study conducted from August 2004 till January 2006. Patients of all age groups and both genders with diagnosis of chronic ITP were included. Treatment protocol and criteria for response assessment was explained. RESULTS During 17 months period, 86 patients with chronic ITP were analyzed. Non-responders to first line therapy were 74 patients who ultimately required splenectomy. Complete response (CR) was had in 37 (50.7%) patients, 10 (13.7%) and 27 (36.5%) had partial response (PR) and no response (NR) respectively. Analysis of variables like younger age, sex and low platelet count at presentation failed to show any significant influence on response to first line treatment. However response to splenectomy was found to be higher in patients who had initial complete or partial response with steroids and later relapsed and the platelet count was more than 300x10(9)/L on day 14 of surgery. CONCLUSION Splenectomy remains the most effective treatment of chronic ITP. No significant factor was identified which predicted initial response to first line treatment. However patients who initially responded to steroids and had platelet counts above 300 X109/L about a fortnight after splenectomy showed promising results post-operatively (p=0.003 and p=0.001).
Collapse
Affiliation(s)
- Naveen Naz Syed
- Department of Pathology and Microbiology, Aga Khan University Hospital, Karachi
| | | | | | | | | | | | | |
Collapse
|
30
|
Aubin E, Lemieux R, Bazin R. Absence of cytokine modulation following therapeutic infusion of intravenous immunoglobulin or anti-red blood cell antibodies in a mouse model of immune thrombocytopenic purpura. Br J Haematol 2007; 136:837-43. [PMID: 17341270 DOI: 10.1111/j.1365-2141.2007.06495.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
Human intravenous immunoglobulin (IVIg) and anti-D immunoglobulin preparations are used in the treatment of immune thrombocytopenic purpura (ITP). One mechanism proposed to explain their therapeutic effects in ITP patients is the induction of expression of anti-inflammatory cytokines, such as interleukin (IL)-10 or IL-1ra, leading to a reduction of phagocytic activity of the reticuloendothelial system. However, increased expression of pro-inflammatory cytokines was also noted following treatment of ITP patients, raising doubt on the actual contribution of anti-inflammatory cytokines in the therapeutic effects of IVIg and anti-D immunoglobulins. The present study evaluated the in vivo modulation of expression of a large array of inflammatory cytokines using a mouse model of thrombocytopenia. IVIg was not found to modulate cytokine expression although it efficiently prevented thrombocytopenia. In contrast, protective (M1/69) and non-protective (TER-119) anti-mouse red blood cell (RBC) antibodies (mimicking anti-D treatment) both increased the expression of CXCL-1 and CXCL-5. Thus, there was no relationship between inflammatory cytokine expression and prevention of thrombocytopenia by IVIg or anti-mouse RBC in the ITP mouse model. These results suggest that the increase in cytokine expression observed in ITP patients following IVIg or anti-D infusion is not required for their therapeutic effects but may rather represent a side-effect of the treatment.
Collapse
Affiliation(s)
- Eric Aubin
- Department of Research and Development, Héma-Québec, QC, Canada
| | | | | |
Collapse
|
31
|
Leszczyńska K, Makowska B, Preis K, Królikowska B, Boćkowski M, Ciach K. [The case of spleen's tumor and trombocytopenia in pregnant women]. Ginekol Pol 2006; 77:876-80. [PMID: 17378128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/14/2023] Open
Abstract
The women with spleen's tumor and trombocytopenia was diagnosed and observed during pregnancy, labour and puerperium. The lowest level of thrombocytes (50 K/microl) was detected in 32nd week of pregnancy. Termination of the pregnancy by cesarean section was performed because of a big risk for the mother and child (tumor's crack, haemorrhage, infection). The same time the splenectomy was conducted. The results were successful.
Collapse
|
32
|
Hashino S. [Heliobacter pylori-related thrombocytopenic purpura]. Nihon Saikingaku Zasshi 2006; 61:381-9. [PMID: 17191693 DOI: 10.3412/jsb.61.381] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Affiliation(s)
- Satoshi Hashino
- Department of Gastroenterology and Hematology, Hokkaido University Graduate School of Medicine
| |
Collapse
|
33
|
|
34
|
Abstract
In the past few years, advances in the understanding of the pathophysiology of thrombotic thrombocytopenic purpura (TTP) has made great strides; however, this has yet to significantly impact the clinical care of patients. Although the use of daily plasma exchange is evidence-based and well established, many of the facets of clinical care remain largely empiric. Our laboratory has had a sustained interest in studying and optimizing the use of plasma exchange in TTP patients. This article presents a summary of how our clinical service approaches TTP patients and manages commonly occurring problems.
Collapse
Affiliation(s)
- Mark E Brecher
- Department of Pathology and Laboratory Medicine, University of North Carolina Hospitals, Chapel Hill, North Carolina 27514, USA.
| |
Collapse
|
35
|
Abstract
Thrombocytopenia can have several causes, including the use of certain drugs. The mechanism behind drug-induced thrombocytopenia is either a decrease in platelet production (bone marrow toxicity) or an increased destruction (immune-mediated thrombocytopenia). In addition, pseudothrombocytopenia, an in vitro effect, has to be distinguished from true drug-induced thrombocytopenia. This article reviews literature on drug-induced immune thrombocytopenia, with the exception of thrombo-haemorrhagic disorders such as thrombotic thrombocytopenic purpura and heparin-induced thrombocytopenia and thrombosis. A literature search in PubMed combined with a check of the reference lists of all the retrieved articles resulted in 108 articles relevant to the subject. The drug classes that are most often associated with drug-induced immune thrombocytopenia are cinchona alkaloid derivatives (quinine, quinidine), sulfonamides, NSAIDs, anticonvulsants, disease modifying antirheumatic drugs and diuretics. Several other drugs are occasionally described in case reports of thrombocytopenia; an updated review of these case reports can be found on the internet. A small number of epidemiological studies, differing largely in the methodology used, describe incidences in the magnitude of 10 cases per 1 000 000 inhabitants per year. No clear risk factors could be identified from these studies. The underlying mechanism of drug-induced immune thrombocytopenia is not completely clarified, but at least three different types of antibodies appear to play a role (hapten-dependent antibodies, drug-induced, platelet-reactive auto-antibodies and drug-dependent antibodies). Targets for drug-dependent antibodies are glycoproteins on the cell membrane of the platelets, such as glycoprotein (GP) Ib/IX and GPIIb/IIIa. Diagnosis of drug-induced immune thrombocytopenia may consist of identifying clinical symptoms (bruising, petechiae, bleeding), a careful evaluation of the causal relationship of the suspected causative drug, general laboratory investigation, such as total blood count and peripheral blood smear (to rule out pseudothrombocytopenia), and platelet serology tests. The sensitivity of these tests is dependent on factors such as the concentration of the drug in the test and the potential sensitisation of the patient by metabolites instead of the parent drug. Drug-induced immune thrombocytopenia can be treated by withholding the causative drug and, in severe cases associated with bleeding, by platelet transfusion. Although drug-induced thrombocytopenia is a relatively rare adverse drug reaction, its consequences may be severe. Therefore it is important to extend our knowledge on this subject. Future research should focus on the identification of potential risk factors, as well as the exact mechanism underlying drug-induced thrombocytopenia.
Collapse
|
36
|
Masseau A, Guitton C, Bretonnière C, Renard B, Villers D, Hamidou M. Échanges plasmatiques dans les formes graves de purpura thrombopénique immunologique aigu. Rev Med Interne 2005; 26:824-6. [PMID: 16084628 DOI: 10.1016/j.revmed.2005.06.009] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2005] [Accepted: 06/02/2005] [Indexed: 11/29/2022]
Abstract
INTRODUCTION High dose steroids and intravenous immunoglobulins are the gold treatment of acute immune thrombocytopenic purpura, before splenectomy for severe and refractory forms of the disease. Authors report two cases of severe acute refractory immune thombocytopenia with a dramatic response to plasma exchanges. EXEGESIS The first case was an idiopathic form, complicated by hemorragic peritoneal effusion. After failure of steroids, intravenous immunoglobulins and splenectomy and 2 courses of rituximab, plasmapheresis normalized in 3 days platelet count. In the second observation, ITP was associated to systemic lupus with antiphospholipids antibodies and multivisceral failure, despite steroids and intravenous immunoglobulins. After 3 plasma exchanges, platelet count was normalized, and the patient is under remission after 24 months follow-up. CONCLUSION Plasmapheresis must be evaluated as an emergency treatment in refractory forms of acute immune thrombocytopenic purpura.
Collapse
Affiliation(s)
- A Masseau
- Service de médecine interne (Pr Planchon), CHU Hôtel-Dieu, Place Alexis-Ricordeau, Nantes 44093 Nantes cedex, France
| | | | | | | | | | | |
Collapse
|
37
|
Abstract
Cyclic thrombocytopenia is a rare condition characterized by regular fluctuations in the platelet count, resulting in bleeding at the time of platelet count nadir. We evaluated a male patient whose platelet count cycled between <10x10(9)/L and a maximum of >1300x10(9)/L over a median of every 42 days (range, 28-57 days). Antiplatelet antibodies were present at highest titer just prior to platelet nadirs. A pathologic expansion of CD3+CD57+ large granular lymphocytes (LGLs) along with a clonal rearrangement of the T-cell receptor (TCR) gamma gene in circulating T cells was detected. LGLs decreased in response to treatment with cyclosporine-A (CsA), but the cycling of the platelet count continued. This is the first report of cyclic thrombocytopenia associated with a T-LGL lymphoproliferative disorder.
Collapse
Affiliation(s)
- Patrick F Fogarty
- Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
| | | | | | | |
Collapse
|
38
|
Bierling P. [Thrombocytopenia]. Rev Prat 2005; 55:1355-61. [PMID: 16138604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Affiliation(s)
- Philippe Bierling
- Laboratoire d'Immunologie Leucoplaquettaire, EFS lle-de-France, Hôpital Henri Mondor, 94000 Créteil.
| |
Collapse
|
39
|
Abstract
The treatment of patients with immune thrombocytopenic purpura (ITP) is changing rapidly, as new agents demonstrate the capability of improving outcomes and decreasing toxicity. Prior to 1981, the only effective treatment options available to increase platelet counts in persons with ITP were corticosteroids and splenectomy. In recent years, intravenous immunoglobulin (IVIg) and intravenous Rh immunoglobulin (IV RhIg) have demonstrated efficacy comparable to that of corticosteroids for increasing platelet counts in ITP. In addition, IVIg and IV RhIg have demonstrated efficacy for maintaining corticosteroid-induced increased platelet counts by periodic infusion, causing a transient impairment of reticuloendothelial clearance function (medical splenectomy). Thus, the time-proven efficacy of corticosteroids for initial treatment of ITP (induction) may now be supplemented with IVIg or IV RhIg infusions for patients requiring ongoing treatment to support a timely and complete steroid taper, while sustaining the increased platelet count (maintenance) with less toxicity. Several investigators have reported that rituximab (anti-CD20) induced sustained remissions with minimal toxicity, in patients with chronic ITP. These reports are promising and, if confirmed, will provide another effective (spleen-sparing) option for managing acute ITP and a long-awaited option for patients who have had a splenectomy and are refractory to conventional agents. Other treatments, including danazol, azathioprine, cyclophosphamide, vinca alkaloids and cyclosporin A, have advocates, but evidence of their efficacy is limited to relatively small and mostly uncontrolled clinical trials. In our opinion, these agents should be reserved for symptomatic thrombocytopenia after refractoriness to corticosteroids, IVIg, IV RhIg, splenectomy and rituximab has been clearly established.
Collapse
Affiliation(s)
- S Gerald Sandler
- Georgetown University Hospital, Department of Laboratory Medicine, 3800 Reservoir Road, NW, Washington, DC 20007, USA.
| | | |
Collapse
|
40
|
Ranasinghe JS, Tjin-A-Tsoi EW, Lewis MC. An unusual presentation of idiopathic thrombocytopenic purpura in pregnancy. J Clin Anesth 2005; 17:66-8. [PMID: 15721733 DOI: 10.1016/j.jclinane.2004.03.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2003] [Accepted: 03/16/2004] [Indexed: 10/25/2022]
Abstract
A 35-year-old, 39-week pregnant woman underwent an uneventful emergent cesarean delivery for suspected placental abruption or uterine dehiscence. Given the urgency of the situation and the unremarkable airway anatomy, general anesthesia was the chosen technique. Four hours after her surgery, she returned to the operating room for persistent vaginal bleeding. Hematology tests performed before the cesarean delivery revealed severe thrombocytopenia. This was later diagnosed as idiopathic thrombocytopenia, which was treated successfully with steroid therapy.
Collapse
Affiliation(s)
- J Sudharma Ranasinghe
- Department of Anesthesiology, University of Miami School of Medicine, Miami, FL 33101, USA
| | | | | |
Collapse
|
41
|
Abstract
Diagnosis and management of congenital and acquired bleeding disorders in children requires not only an understanding of the unique characteristics of pediatric hemostasis but also the natural course of bleeding disorders in children, which may differ substantially from the course observed in adult patients. In this article, three bleeding disorders of great importance to the pediatric hematologist are reviewed: neonatal alloimmune thrombocytopenia (NAIT), hemophilia and immune-mediated thrombocytopenic purpura (ITP). Current aspects of management are outlined. The unique physiology of transplacental transfer of maternally derived anti-platelet antibodies can result in neonatal immune thrombocytopenia, a significant cause of morbidity and mortality from bleeding in affected infants. For patients with hemophilia, approaches to treatment have shifted over the past decade from on-demand therapy to prophylaxis, either primary of secondary, resulting in delay of onset or complete avoidance of hemophilic arthropathy. Hemophilic inhibitors often develop in young children, prompting the need for a thorough understanding of the use of bypassing agents as well as immune tolerance induction in the young child. Finally, although several management strategies for ITP of childhood have been shown to improve the platelet count, side effects associated with corticosteroids, IVIg, anti-D and splenectomy force the practitioner to also consider the option of carefully observing, but not treating, the child with ITP.
Collapse
MESH Headings
- Antigens/immunology
- Blood Platelets/immunology
- Child
- Female
- Hemophilia A/blood
- Hemophilia A/immunology
- Hemophilia A/therapy
- Humans
- Infant, Newborn
- Infant, Newborn, Diseases/blood
- Infant, Newborn, Diseases/immunology
- Infant, Newborn, Diseases/therapy
- Maternal-Fetal Exchange
- Platelet Count
- Pregnancy
- Purpura, Thrombocytopenic/blood
- Purpura, Thrombocytopenic/therapy
- Purpura, Thrombocytopenic, Idiopathic/blood
- Purpura, Thrombocytopenic, Idiopathic/immunology
- Purpura, Thrombocytopenic, Idiopathic/therapy
- Thrombocytopenia, Neonatal Alloimmune/blood
- Thrombocytopenia, Neonatal Alloimmune/therapy
Collapse
Affiliation(s)
- Catherine S Manno
- The Children's Hospital of Philadelphia, 34th & Civic Center Blvd., Rm. 9518 Main Bldg., Philadelphia, PA 19104, USA.
| |
Collapse
|
42
|
Mohanty D, Kulkarni B, Ghosh K, Nair S, Khare A. Human platelet specific antigens and their importance. Indian Pediatr 2004; 41:797-805. [PMID: 15347867] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/30/2023]
Affiliation(s)
- Dpika Mohanty
- Institute of Immunohematology (ICMR), 13th Floor, KEM Hospital New Building, Parel, Mumbai 400012, India.
| | | | | | | | | |
Collapse
|
43
|
Affiliation(s)
- Yukako Yoshikane
- Department of Pediatrics, Kyushu Kosei Nenkin Hospital, Fukuoka, Japan.
| | | | | | | | | |
Collapse
|
44
|
Abstract
This review summarizes data on haematopoietic stem cell transplantation (HSCT) to treat severe, refractory, haematological autoimmune cytopenia. A phase II study by the National Institutes of Health of the USA has presented data on autologous HSCT in 14 patients with immune thrombocytopenia or Evans' syndrome, with no early deaths and a response rate of 57%. The registry of the European Group for Blood and Marrow Transplantation holds data on 38 transplants, autologous for 27 and allogeneic for 9 patients. The disease entities and regimens used were more heterogeneous. The conditions encountered were autoimmune haemolytic anaemia, Evans' syndrome, immune thrombocytopenia, pure red cell aplasia, pure white cell aplasia and thrombotic thrombocytopenic purpura. Patients had long-standing disease, having failed multiple prior treatments. Among 26 evaluable patients mobilized for autologous HSCT, 3 died of treatment-related causes, 1 died of disease progression, 7 were non-responders, 6 patients had transient responses, and 9 had sustained partial or complete remission. Of the 7 evaluable patients receiving allogeneic HSCT, 1 died of treatment-related complications, 1 with a transient response died of progressive disease, and 5 showed a sustained response. Autologous and allogeneic HSCT may induce a response in a considerable proportion of patients with autoimmune cytopenia of long duration.
Collapse
Affiliation(s)
- Jakob R Passweg
- Stem Cell Transplant Team, Hematology Division, Basel University Hospitals, Basel, Switzerland.
| |
Collapse
|
45
|
Mulliken JB, Anupindi S, Ezekowitz RAB, Mihm MC. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 13-2004. A newborn girl with a large cutaneous lesion, thrombocytopenia, and anemia. N Engl J Med 2004; 350:1764-75. [PMID: 15103004 DOI: 10.1056/nejmcpc049002] [Citation(s) in RCA: 72] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Affiliation(s)
- John B Mulliken
- Division of Plastic Surgery, Craniofacial Center, and Vascular Anomalies Center, Children's Hospital , Boston, USA
| | | | | | | |
Collapse
|
46
|
|
47
|
Abstract
Post-operative thrombotic thrombocytopenic purpura (TTP) is a recently recognised life-threatening clinical syndrome with considerable similarity to classic TTP in presentation and response to early treatment with plasma exchange. To date, 29 cases of TTP associated with surgery have been reported. The majority of cases have complicated vascular surgeries, with a few cases seen following gastrointestinal or orthopaedic procedures. Characteristically, patients develop microangiopathic haemolytic anaemia and consumptive thrombocytopenia 5 to 9 days following surgery with variable presence of fever, impaired renal function and altered mental status. The pathogenesis of post-operative TTP is speculative but may involve the release of large amounts of high-molecular-weight von Willebrand factor (vWF) multimers due to endothelial damage resulting from surgery in the setting of marginal levels of vWF-cleaving enzyme. The myriad of common post-surgical complications that may present with clinical manifestations similar to TTP may result in confusion with the potential for delay in the initiation of life-saving plasma-exchange therapy. It is important that physicians be alert to the phenomenon of post-operative TTP so that prompt recognition and treatment will prevent serious morbidity or mortality.
Collapse
Affiliation(s)
- T A Naqvi
- Division of Hematology/Oncology, Department of Medicine, Wright State University School of Medicine, Dayton, OH 45428, USA
| | | | | |
Collapse
|
48
|
Sandler SG. Review: immune thrombocytopenic purpura: an update for immunohematologists. Immunohematology 2004; 20:112-7. [PMID: 15373659] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/30/2023]
Abstract
Immune thrombocytopenic purpura (ITP) is an acquired disease in which autoantibodies to platelets cause their sequestration and destruction by mononuclear macrophages, principally in the spleen. If increased production of platelets by megakaryocytes does not compensate for platelet destruction, the number of circulating platelets decreases (thrombocytopenia), resulting in a characteristic bleeding tendency (purpura). While most children with the disease experience a relatively short and benign clinical course, ITP in adults often lasts more than 6 months (chronic ITP) and is resistant to conventional treatment (corticosteroids, intravenous immune globulin, or splenectomy). The goal of medical management is to increase the platelet count to a safe level, without the risks of bacterial infections associated with splenectomy or toxicity from prolonged corticosteroid therapy. Splenectomy increases platelet counts in hours to days in most patients with acute ITP, but nearly 50 percent experience recurrent thrombocytopenia by 5 years postsplenectomy.
Collapse
Affiliation(s)
- S G Sandler
- Transfusion Medicine, Department of Laboratory Medicine, Georgetown University Hospital, 3800 Reservoir Road, NW, Washington, DC 20007, USA
| |
Collapse
|
49
|
|
50
|
Sajid R, Adil SN, Fadoo Z, Sabir S, Khurshid M. Use of intravenous anti-D in patients with refractory and relapsed immune thrombocytopenic purpura. J PAK MED ASSOC 2003; 53:537-9. [PMID: 14738260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/28/2023]
Abstract
OBJECTIVE To determine the response to i.v. anti-D and its comparison with splenectomy as second line therapy in refractory and relapsed cases of ITP, in the Aga Khan University Hospital, Karachi. METHODS A total of 23 patients with chronic ITP were treated with either anti-D or splenectomy as second line treatment. The patients were assessed for time to achieve a response to second line treatment, duration of response and adverse events. RESULTS There were 12 patients in the anti-D group and 11 in the splenectomy group. The mean platelet count at presentation was 9,000/cumm. The mean age was 8.9 years and 13.0 years and the male to female ratio was 1:1 and 1:1.2 in anti-D and splenectomy group respectively. 54.5% of the patient in the anti-D group responded compared to 81.8% in the splenectomy group. Median time to achieve a response was 7 days in the anti-D group and 1 day in the splenectomy group. Mean time to relapse was 87.8 days in the anti-D group and 55.4 days in the splenectomy group. No adverse events were recorded for any of the infusions of anti-D and none of the patients had more than 0.5 gm/dl fall in the hemoglobin level following anti-D infusion. CONCLUSION It was thus concluded that Anti-D is a relatively safe, convenient and effective therapy for chronic ITP and can be used as a splenectomy sparing agent when treatment is clinically indicated.
Collapse
Affiliation(s)
- R Sajid
- Department of Pathology, The Aga Khan University, Karachi
| | | | | | | | | |
Collapse
|